DESCRIPTION

TRAVIS.A75 is an oil based solution of trenbolone acetate
for IM injection. Trenbolone is an

anabolic steroid with significant anabolic and androgen
effects. The fast acting ester

produces a rapid increase in serum trenbolone levels which
remain elevated for several days

thereafter. Trenbolone promotes significant increases in
strength, muscle anabolism,

appetite, and aggression; and has been demonstrated to
reduce body fat.

INDICATIONS

Males: Trenbolone use may be indicated in patients where
substantial weight gain and

increases in musculature are required for patient health
after substantial losses of body

mass, especially in instances where caloric intake is
limited and other anabolic therapies

have previously failed. The physician and patient must
consider the risks of therapy versus

the potential benefits.

CLINICAL PHARMACOLOGY

Anabolic steroids are synthetic derivatives of testosterone.
Certain clinical effects and

adverse reactions demonstrate the androgenic properties of
these drugs. Complete

dissociation of anabolic and androgenic effects has not been
achieved. The actions of

anabolic steroids are thus similar to those of male sex
hormones. Anabolic steroids

suppress the gonadotropic functions of the pituitary and may
exert a direct effect upon the

testes. During exogenous administration of anabolic
androgens, endogenous testosterone

release is inhibited through inhibition of pituitary luteinizing
hormone (LH). At large doses,

spermatogenesis may be suppressed through feedback
inhibition of pituitary folliclestimulating hormone (FSH).

Trenbolone binds strongly to the androgen receptor and its
action is generally considered to

derive therefrom. It produces significant anabolism even
during periods of limited caloric

restriction. The literature offers conicting reports of the
susceptibility of trenbolone to

aromatize into estrogen or reduce to a dihydrotestosterone
derivative. Rat studies have

suggested that trenbolone may exert effects typically
associated with dihydrotestosterone

through a non-DHT pathway potentially with direct receptor
action. It has been suggested

that trenbolone may reduce cortisol production through an
indeterminate pathway of activity

upon glucocorticoid receptors.

Trenbolone has been demonstrated to promote muscle growth,
appetite, aggression, and

the production of red blood cells through the production of
erythropoietic stimulating factor.

Trenbolone is suspected of selective binding of the
progesterone receptor potentially acting

as both an agonist and an antagonist. It has been suggested
that trenbolone is capable of

binding to the prolactin receptor. Thus serum progesterone
and serum prolactin levels

should be monitored during treatment and if elevated
anti-progesterone and anti-prolactin

agents should be considered.

ADVERSE REACTIONS

Male: Gynecomastia, excessive frequency and duration of
penile erections, oligospermia.

Skin and Appendages: Hirsutism, male pattern baldness and
acne, gynecomastia.

Fluid/electrolyte Disturbances: Retention of sodium,
chloride, water, potassium, calcium,

and inorganic phosphates.

Gastrointestinal: Nausea, cholestatic jaundice, alterations
in liver function tests;

hepatocellular neoplasms, peliosis hepatitis, hepatic
adenomas, nephritis, and cholestatic

hepatitis.

Hematologic: Suppression of clotting factors II, V, VII,
& X; bleeding in patients on anticoagulant therapy.

Neurological: Increased libido, headache, anxiety,
depression, extreme agitation, irritability,

and generalized paresthesia. Trenbolone may cause severe
aggressive behavior.

Other: Serum lipid changes. hypertension, hypercalcaemia,
hypertension, oedema,

priapism, and potentiation of sleep apnea.

DRUG INTERACTIONS

Patients on oral anticoagulant therapy require close
monitoring especially when androgens

are started or stopped.

Diabetics: androgens may alter the metabolism of oral
hypoglycemic agents or may change

insulin sensitivity in patients with diabetes mellitus which
may require adjustment of dosage

of insulin and other hypoglycemic drugs.

May alter metabolism of cyclosporins.

Avoid other hepatotoxic medications.

CONTRAINDICATIONS

Patients with known hypersensitivity to any ingredients in
this product.

Patients with known or suspected carcinomas of the breast,
testis, or prostate.

Patients with severe heart disease, liver disease, or kidney
disease or with a history of

epilepsy.

Products containing androgens should not be used in women as
they may cause virilization

and fetal harm.

PRECAUTIONS

Women, children and elderly males should not use.

Trenbolone should be used with extreme caution and with the
lowest dosage and duration of

treatment necessary for clinical response pursuant to the
advice of a qualified physician.

Because androgens may alter serum cholesterol concentration,
caution should be used

when administering these drugs to patients with a history of
myocardial infarction or

coronary artery disease.

Trenbolone may increase aggressiveness and cause psychiatric
changes. At the first sign of

psychiatric changes discontinue use of trenbolone and
contact a physician.

Due to its hepatotoxicity, liver functions should be
monitored. Discontinue on signs of

jaundicing.

PATIENT MONITORING

Serum Cholesterol, HDL, LDL, TG. Hemoglobin and Hematocrit,
Hepatic function tests –

AST/ALT

Prostatic specific antigen – PSA, Testosterone: total, free,
and bioavailable.

Dihydrotestosterone & Estradiol

Progesterone, Prolactin, Blood Pressure

Male patients over 40 should undergo a digital rectal
examination and evaluate PSA prior to

androgen use. Periodic evaluations of the prostate should
continue while on androgen

therapy, especially in patients with difficulty in urination
or with changes in voiding habits.

DOSAGE AND ADMINISTRATION

Adult male: 50 – 100mg injected IM every 3 days for duration
limited to 4 weeks under care of

physician.

PRESENTATION

TRAVIS.A75(75mg/ml) – 10 ampules of 1mg/ml each.